$BEAM

Beam Therapeutics (BEAM) appointed Eric Foster as chief commercial officer. Foster will lead the company's commercial strategy as it advances candidates in hematology and genetic diseases. Beam is a biotech focused on precision genetic medicines.

Beam Global reported a 174% sequential revenue increase in Q2 2026, driven by backlog conversions. The company diversified into global energy, mobility, and intelligence sectors, with Europe matching U.S. revenue. Battery business gained traction in drones, robotics, and defense. Yuma relocation cut costs. Management expects margin expansion, targets AI data centers, and focuses on recurring revenue models. The company remains debt-free with a $100M credit line. Q2 gross margin improved by 30 pe

Simply Wall St reports Beam Therapeutics (NASDAQ:BEAM) missed Q2 expectations, with revenue of about $490k, 97% below forecasts, and a loss of $1.18 per share, 7.5% worse than modeled. For 2026, analysts cut revenue to $53.8m (down from $78.9m) and forecast EPS loss rising to $4.40. Consensus price target stays near $52.15.

Beam Therapeutics (BEAM) reported a wider-than-expected Q2 2026 loss of $1.18 per share versus a $1.00 consensus loss. Revenue fell to $0.5 million, below a $30 million estimate, from $8.5 million a year earlier. Cash and securities were about $1.2 billion, supporting operations into mid-2029. Pipeline updates include risto-cel and BEAM-302 accelerated-approval plans.

Beam Therapeutics reported 2Q 2026 results in its 10-Q. Revenue was $0.5M, down from $8.5M a year earlier. Net loss attributable to Beam was $(122.7)M versus $(102.1)M, and diluted EPS was $(1.18) versus $(1.00). The company said BEACON risto-cel dosing is complete and a BLA is targeted for year-end 2026.

Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation

Ark Invest’s Cathie Wood has continued buying Beam Therapeutics (BEAM), with the most recent purchases last week totaling about $4 million. Wood’s stake is reported at over $300 million. Beam is advancing base-editing programs, including BEAM-302 for alpha-1 antitrypsin deficiency and risto-cel for sickle cell, with FDA filings expected by end-2026. Beam reported $1.21B cash at Q1 and a net loss of $94.3M.

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Beam Therapeutics (NASDAQ:BEAM) after Prime Medicine’s arbitration resolution. Stranahan set a $47 target price, citing limited impact on Beam because the outcome relates to Prime’s PM647. He said Beam’s focus remains on BEAM-302 biomarker data and execution for alpha-1 antitrypsin deficiency, with Prime viewed as a distant threat.

Prime Medicine said it won a dispute with Beam Therapeutics over gene-editing technology rights related to AATD. Prime expects to start an AATD clinical trial this quarter, and its stock rose about 11% while Beam fell about 2%. Beam said it disagrees and may pursue further action, according to company statements.

Beam Therapeutics shares fell about 5% after an arbitration tribunal ruled for Prime Medicine in a dispute over rights to PM647, an investigational gene editing therapy for Alpha-1 Antitrypsin Deficiency. The tribunal said PM647 is within Prime’s licensed “Field” under a 2019 agreement. The move followed a recent 52-week high and an H.C. Wainwright Buy rating with an $80 target, while broader equities declined on renewed geopolitical risk.